Procedures
All pediatric patients admitted during the study period had their predicted probability of HA-VTE calculatedPatients randomized to the control group received the current standard of care treatment; they were eligible for prophylactic pharmacologic initiation at the discretion of their clinical team, who would identify patients who may benefit and consult the pediatric hematology consult service for recommendations. There were no hospital-wide HA-VTE prophylaxis protocols in place during the study.